Crinetics Pharmaceuticals, Inc.
Crinetics is here for endocrine disease patients who are eager to find therapies that provide effective disease control and more simplicity in their lives.
Funding history
About Crinetics Pharmaceuticals, Inc.
How much funding has Crinetics Pharmaceuticals, Inc. raised?
Crinetics Pharmaceuticals, Inc. has raised $350.0M in total funding.
Where is Crinetics Pharmaceuticals, Inc. headquartered?
Crinetics Pharmaceuticals, Inc. is headquartered in San Diego, CA.
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics is here for endocrine disease patients who are eager to find therapies that provide effective disease control and more simplicity in their lives.
What problem does Crinetics Pharmaceuticals, Inc. solve?
People with endocrine diseases need therapies that let them break through their disease, an area the company frames as underserved by current care.
What's Crinetics Pharmaceuticals, Inc.'s solution?
Crinetics is building an endocrine-rooted pharmaceutical pipeline, including an oral SST2 agonist (paltusotine), an oral ACTH antagonist (atumelnant), and a non-peptide drug conjugate, developed through its own 'Discovery Engine.'
What makes Crinetics Pharmaceuticals, Inc. different?
The page emphasizes being 'singularly focused' as a premier endocrine-rooted global pharmaceutical company, with a proprietary Discovery Engine driving its pipeline (and notes it is being acquired by Vertex Pharmaceuticals).
What makes Crinetics Pharmaceuticals, Inc. notable?
Founded by Scott Struthers, PhD; Vertex Pharmaceuticals has agreed to acquire the San Diego company.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.